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7RESEARCH ARTICLE Open AccessBiomarkers of pulmonary hypertension in
patients with scleroderma: a case–control
study
Zsuzsanna McMahan1, Florian Schoenhoff1,2, Jennifer E. Van Eyk1,3,4,5,6, Fredrick M. Wigley1*
and Laura K. Hummers1Abstract
Introduction: Significant pulmonary vascular disease is a leading cause of death in patients with scleroderma, and
early detection and early medical intervention are important, as they may delay disease progression and improve
survival and quality of life. Although several biomarkers have been proposed, there remains a need to define a
reliable biomarker of early pulmonary vascular disease and subsequent development of pulmonary hypertension
(PH). The purpose of this study was to define potential biomarkers for clinically significant pulmonary vascular
disease in patients with scleroderma.
Methods: The circulating growth factors basic fibroblast growth factor, placental growth factor (PlGF), vascular
endothelial growth factor (VEGF), hepatocyte growth factor, and soluble VEGF receptor 1 (sFlt-1), as well as
cytokines (interleukin [IL]-1β IL-2, IL-4, IL-5, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor-α, and interferon-γ), were
quantified in patients with scleroderma with PH (n = 37) or without PH (n = 40). In non-parametric unadjusted
analyses, we examined associations of growth factor and cytokine levels with PH. In a subset of each group, a
second set of earlier samples, drawn 3.0±1.6 years earlier, were assessed to determine the changes over time.
Results: sFlt-1 (p = 0.02) and PlGF (p = 0.02) were higher in the PH than in the non-PH group. sFlt-1 (ρ = 0.3245;
p = 0.01) positively correlated with right ventricular systolic pressure. Both PlGF (p = 0.03) and sFlt-1 (p = 0.04) positively
correlated with the ratio of forced vital capacity to diffusing capacity for carbon monoxide (DLCO), and both inversely
correlated with DLCO (p = 0.01). Both PlGF and sFlt-1 levels were stable over time in the control population.
Conclusions: Our study demonstrated clear associations between regulators of angiogenesis (sFlt-1 and PlGF) and
measures of PH in scleroderma and that these growth factors are potential biomarkers for PH in patients with
scleroderma. Larger longitudinal studies are required for validation of our results.Introduction
Pulmonary hypertension (PH) is a common complica-
tion of scleroderma, with an estimated 8–12 % of pa-
tients developing pulmonary arterial disease [8, 19].
Significant pulmonary vascular disease is a leading cause
of death in patients with scleroderma, with approximately
30 % of scleroderma-related deaths being attributable
to PH [24]. Early detection of pulmonary arterial* Correspondence: fwig@jhmi.edu
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creativecommons.org/publicdomain/zero/1.0/hypertension (PAH) in patients with scleroderma, together
with early medical interventions, is important, as it may
provide the opportunity to delay disease progression and
improve survival and quality of life [7, 8, 11, 22]. As tar-
geted therapies for PH and PAH in scleroderma improve,
early detection and intervention will become increasingly
important.
Circulating biomarkers have the potential of playing a
significant clin
ical role in defining disease activity and predicting prog-
nosis. Although several biomarkers have been proposed
[1, 2, 6], there remains a need to define a reliable bio-
marker of early pulmonary vascular disease and provides article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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study was to investigate potentially relevant biomarkers
associated with the presence of PH that could ultimately
be tested in a longitudinal cohort study.Methods
Subjects
We selected subjects from the Johns Hopkins Sclero-
derma Center who either met the 1980 American
College of Rheumatology criteria for the diagnosis of
scleroderma or had at least three of five features of
CREST syndrome (calcinosis, Raynaud’s phenomenon,
esophageal dysmotility, sclerodactyly, and/or telangiecta-
sia). Additional selection criteria included the availability
of two plasma samples drawn at least 6 months apart
and data defining the presence or supporting the ab-
sence of PH. Patients were scored by clinicians at rou-
tine clinical visits as having or not having PH based on
available data (“yes” or “no” on the clinical research
form). Patients seen between 2005 and 2009 and docu-
mented as having PH were then further screened for in-
clusion in the study. Verification of the diagnosis of PH
was done through review of right heart catheterization
(RHC) data, data obtained from echocardiograms (echo),
and chart reviews. Patients were defined as having PH
if they had a resting RHC mean pulmonary arterial
pressure (mPAP) ≥25 mmHg. Additional subgroups
included the following groups according to World
Health Organization (WHO) PH guidelines: (1) PAH
with mPAP ≥25 mmHg, pulmonary capillary wedge
pressure (PCWP) ≤15 mmHg, and forced vital capacity
(FVC) ≥70 %; (2) PH and significant restrictive venti-
latory defects (RVD) (mPAP ≥25 mmHg, PCWP <15
mmHg, and FVC <70 %); and (3) pulmonary venous
hypertension (PVH) (mPAP ≥25 mmHg, PCWP >15
mmHg). Control subjects had no clinical symptoms
suggestive of PH and had a diffusing capacity for car-
bon monoxide (DLCO) >60 %, an echo demonstrating
right ventricular systolic pressure (RVSP) <45 mmHg,
normal right atrial size (<16 cm2), and normal right
ventricular function [5].
All patients and controls were followed at the Johns
Hopkins Scleroderma Center, where clinical and labora-
tory data are collected prospectively every 6 months.
Clinical data were selected at the time closest to the
blood sample and included Medsger severity scores [20],
demographics, pulmonary function tests, echocardio-
grams, and RHCs. FVC and DLCO were standardized
for age and sex and reported as the percentage of the
predicted value [9, 14]. A disproportionately low DLCO
was defined by a ratio of forced vital capacity to diffusing
capacity for carbon monoxide (FVC/DLCO) ≥1.6. The
study was approved by the Johns Hopkins University’sInstitutional Review Board, and all enrolled patients
signed informed consent forms.Samples
Plasma samples in the scleroderma PH group (cases;
n = 37) were drawn (in sodium citrate) after the diag-
nosis of PH was established. In the non-PH group
(controls; n = 40), the most recent samples available
were selected for analysis. In addition, a second, earl-
ier plasma sample was selected from a subset of pa-
tients in the PH group (n = 12) and the non-PH
group (n = 21) who had an available sample drawn at least
6 months before the first sample (cases, mean±standard
deviation [SD] of 3.9±1.7 years before; controls, 2.5±1.4
years before) and before the diagnosis of PH in the
case group. These samples were included to evaluate
the variability of factor levels over time. Plasma sam-
ples were stored at −80 °C from collection until the
time of analysis.
Samples were thawed and centrifuged with 15,000
relative centrifugal force for 15 minutes immediately be-
fore use. The growth factor levels (basic fibroblast
growth factor [bFGF], placental growth factor [PlGF],
vascular endothelial growth factor [VEGF], hepatocyte
growth factor [HGF], VEGF receptor 1 [sFlt-1]) and cy-
tokines (interleukin [IL]-1β, IL-2, IL-4, IL-5, IL-8, IL-10,
IL-12, IL-13, tumor necrosis factor [TNF]-α, interferon
[IFN]-γ) were measured using a ruthenium-based elec-
trochemiluminescence platform (Meso Scale Discovery,
Gaithersburg, MD, USA). Biomarkers were chosen based
on preliminary or published data suggesting a possible
biological association with PH and/or scleroderma-
associated PH [3, 12, 13].
Duplicate samples were run using 25 μl of plasma per
well. The results were considered valid when the per-
centage recovery was 100±20 %, the percentage of coeffi-
cient of variation (CV) was <20 %, the intra-assay CV
was <10 %, and the interassay CV was <20 % and if 85 %
of the samples of a run met these specifications. Each
96-well plate included standard curves that were used to
determine concentrations and the lower limits of detec-
tion (LLOD) and quantification (LLOQ) [15, 18].Statistical analysis
Biomarkers with >25 % of their values outside the LLOQ
of the assay were not analyzed further owing to sample
size limitations. Differences in baseline characteristics
between patients with PH (n = 37) and those without
PH (n = 40) were examined with χ2 tests. Student’s t
tests were used to compare the differences in means of
normally distributed continuous variables in patients
with and without PH. The Wilcoxon-Mann–Whitney
test was used to compare the distribution of non-
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in patients with and without PH. This test was also used
to define the association between biomarkers and other
dichotomous demographic characteristics, including sex,
race, cutaneous subtype, antibody status (anti-centromere
protein [anti-CENP], anti-topoisomerase-1 [anti-Topo], and
anti-ribonucleoprotein [anti-RNP]), and history of smoking.
The relationship between the biomarker levels and other
continuous variables, including age, disease duration
(both from Raynaud’s and non-Raynaud’s symptom on-
set), DLCO, FVC/DLCO ratio, RVSP, mPAP, and the pa-
tient’s maximum Raynaud’s Medsger severity scores were
examined with the Spearman correlation test. Limited
multivariable regression modeling was done to evaluate
the adjusted association between PH and the biomarkers
of interest. Dependent variables included in the model
were variables that were potentially relevant confounders
in the univariate analyses.
The Wilcoxon-Mann–Whitney test was also used to
evaluate differences in biomarker levels in patients with
and without PH at the early time point to determine if dif-
ferences in biomarker levels before the diagnosis of PH are
informative. The difference in biomarker levels before and
after the diagnosis of PH was evaluated using the non-Table 1 Baseline demographic and clinical characteristics of the ent
Pulmonary
(n = 37)
Sex, n (%)
Male 3 (8.1)
Female 34 (91.9)
Mean age at last sample, yr (range) 64.9 (38–89
Race, n (%)
White 30 (81.1)
African American 7 (18.9)
Median disease duration, yr (IQR)a 10.7 (1.4–16
Limited SSc, n (%) 31 (83.8)
Ever smoker, n (%) 12 (32.4)
Median modified Rodnan skin score (0–51) (IQR) 7.0 (5.0–15.0
Severe Raynaud’s symptoms, n (%)b 29 (78)
FVC, mean±SD 67.5±21.2
DLCO, mean±SD 48.4±18.9 (n
Median RVSP (IQR) 60 (48–74.5
Anti-Scl-70, n (%) 5 (13.5)
Anti-RNP, n (%) 4 (11.4) (4/3
Anti-centromere, n (%) 17 (46.0)
Abbreviations: DLCO diffusing capacity of carbon monoxide, FVC forced vital capacit
pressure, Scl-70 topoisomerase-1, SD standard deviation, SSc scleroderma
Non-parametric continuous data were evaluated using the Wilcoxon-Mann–Whitney
aFrom time of Raynaud’s onset
bBased on Medsger severity score (Medsger score >1 = severe Raynaud’s)parametric sign test. The stability of the biomarkers over
time was evaluated by comparing biomarker levels among
controls across the two time points with the non-
parametric sign test. A subgroup analysis using analysis of
variance was done to evaluate differences in biomarker
levels in PAH, PVH, and PH-RVD. The data were analyzed
using STATA version 11 statistical software (StataCorp,
College Station, TX, USA).Results
Characteristics of the patient population
The dataset comprised 77 patients: 37 patients with PH
and 40 control subjects without PH (Table 1). The mean
ages at sample collection were 65 (range, 38–89) years in
the PH group and 56 (range, 27–73) years in the non-PH
group (p = 0.001). As PH is more likely to present with
increasing age [20], the age difference was expected. The
median disease durations from the time of sample collec-
tion were 10.7 (interquartile range [IQR], 1.4–16.0) years
in the PH group and 8.2 (IQR, 3.8–9.7) years in the non-
PH group (p = 0.02). Differences related to sex (p = 1.00)
and scleroderma subtype (p = 0.06) were not significant.
Patients with PH were more frequently African Americanire study population
hypertension Controls
(n = 40)
p value
1.00
4 (10.0)
36 (90.0)
) 55.9 (27–73) <0.01
0.03
39 (97.5)
1 (2.5)
.0) 8.2 (3.8–9.7) <0.01
26 (65) 0.06
15 (37.5) 0.64
) 7.0 (4.5–18.0) 0.97
16 (40) <0.01
88.1±15.9 <0.01
= 36) 92.1±24.0 <0.01
) (n = 36) 33 (27–36) (n = 25) <0.01
7 (17.5) 0.63
5) 2 (5.9) (2/34) 0.67
13 (32.5) 0.23
y, IQR interquartile range, RNP ribonucleoprotein, RVSP right ventricular systolic
test and are represented as median (IQR)
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Twenty-eight of 37 patients with PH were receiving treat-
ment for PH at the time of the study (Additional file 1:
Table S1). WHO functional classes represented in the
PH population included class 1 (n = 13), class 2 (n = 10),
class 3 (n = 6), and class 4 (n = 8). Of the PH patients,
54 % (n = 20) had significant RVD, whereas significant
RVD was present in only 7.5 % (n = 3) of those without
PH (p < 0.001). Sixteen patients had PAH without signifi-
cant RVD, 13 had PH and significant RVD, 8 patients had
PVH (mPAP ≥25 mmHg, PCWP >15 mmHg), 5 of whom
had significant RVD (FVC <70% of predicted).Evaluating the association of biomarkers with clinical and
demographic variables and the presence of pulmonary
hypertension across cases and controls
We eliminated IL-1β, IFN-γ, IL-2, IL-4, IL-10, and IL-13
from the analysis, given that more than 25 % (27–65 %)
of their enzyme-linked immunosorbent assay values
were out of the quantifiable range of the assay (mainly
below the LLOD). We found no associations between
the biomarkers and sex, race, cutaneous subtype, anti-
body status (anti-CENP, anti-Topo, anti-RNP), or history
of smoking. We also evaluated the association between
biomarker levels and the continuous variables age, max-
imum Rodnan skin score (range, 0–51), and disease dur-
ation. We found that IL-8 (p = 0.02), TNF-α (p = 0.02),
sFlt-1 (p = 0.02), and HGF (p = 0.01) were associated
with age and that there were no significant associations
between biomarkers and skin score or disease duration.
We then evaluated the association between PH and each
of the measurable biomarkers at the late time point and
found that sFlt-1 (median, 101.8 [interquartile range {IQR},
87.6–149.2] pg/ml vs. 89.7 [65.9–120.7] pg/ml; p = 0.02)
and PlGF (median, 24.8 [IQR, 16.3–31.0] pg/ml vs. 19.1
[15.3–22.9] pg/ml; p = 0.02) are both significantly higher
in patients with PH than in those without PH (Fig. 1a, b).
None of the other biomarkers were associated with PH
(Table 2).
We then performed limited multivariable modeling to
evaluate the adjusted association between PlGF and sFlt-
1 levels and scleroderma-associated PH. We adjusted for
age and severe RVD in our model because they were
potential confounders in the univariate analysis. In these
models, the association between the biomarkers and PH
was not significant, though the power to detect this
association was limited by the small sample size.
To evaluate PH subgroups (PAH, PAH-RVD, and
PVH), for differences in individual biomarker levels, a
sensitivity analysis was done. Biomarker levels were
not significantly different among the PH subtypes. In
addition, biomarker levels were not different based on
whether a patient was taking a prescribed vasodilatorfor PH (prostacyclin/prostaglandins, phosphodiesterase
inhibitors, or endothelial receptor antagonists). The
distribution of these medications across our patient
population is listed in Additional file 2: Table S2.
Evaluating biomarkers and measures of cardiopulmonary
severity
Spearman’s correlation was then used to determine if
there was a relationship between the biomarker levels
and clinical indications of pulmonary disease severity
(DLCO, FVC/DLCO ratio, and RVSP) across cases and
controls. DLCO values were available for 76 of 77 patients.
Interestingly, both PlGF (ρ = −0.31, p = 0.01) and sFlt-1
(ρ = −0.29, p = 0.01) were inversely correlated with DLCO
and were significantly associated with the FVC/DLCO ra-
tio (PlGF, ρ = 0.26, p = 0.03; sFlt-1, ρ = 0.23, p = 0.04)
(Fig. 2). None of the other biomarkers were associated with
these parameters. Both sFlt-1 (ρ = 0.32, p = 0.01) and HGF
(ρ = 0.34, p = 0.01) were associated positively with RVSP,
which was not the case for the other biomarkers.
Evaluating biomarker levels and measures of peripheral
vascular severity
We then explored whether biomarker levels correlate
with clinical indications of peripheral vascular disease
in scleroderma (n = 77). First, we correlated biomarker
levels with measures of Raynaud’s severity in sclero-
derma [17, 23]. Interestingly, we found that levels of
PlGF significantly correlated with Raynaud’s severity
scores (ρ = 0.29, p = 0.02) (Fig. 3a). sFlt-1 levels also
significantly correlated with Raynaud’s severity scores
(ρ = 0.23, p = 0.04) (Fig. 3b). These associations were
not observed with any of the other cytokines or growth
factors we studied.
Assessment of serial biomarker levels
In the patients who had two plasma samples available,
with the first drawn before the diagnosis of PH (cases
drawn, mean±SD of 3.9±1.7 years before late blood
sample; controls drawn 2.5±1.4 years before late blood
sample), biomarker levels from the prediagnosis sample
(n = 12) were evaluated. These analyses were done to de-
termine if patients who were eventually diagnosed with
PH (n = 12) had biomarker levels at the early time point
significantly different from those of patients who did not
develop PH (n = 21). In the PH group at the early time
point, levels of sFlt-1 (p = 0.02) and IL-12 (p = 0.03), but
not any other markers, were significantly elevated relative
to the non-PH group (Table 3). Levels of PlGF were also
high in the PH group at the early time point, a finding that
neared statistical significance (p = 0.07). At the early time
point, PlGF levels positively correlated with RVSP (ρ =
0.54; p < 0.01; n = 25) and inversely associated with DLCO
(ρ = −0.35; p = 0.06). The inverse association between
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Fig. 1 Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) levels in patients with or without pulmonary hypertension
(PH). a PlGF (median, 25 [interquartile range {IQR}, 16.3–31.0] pg/ml vs. 19.1 [15.3–22.9] pg/ml; p = 0.02) is significantly higher in patients with
scleroderma with PH than in those with scleroderma without PH across the whole cohort at the later time point (n = 33 PH, n = 38 non-PH)
(b) sFlt-1 (median, 102 [IQR, 88–149] pg/ml vs. 90 [66–121] pg/ml; p = 0.02) is significantly higher in patients with scleroderma with PH than in those
with scleroderma without PH across the whole cohort (n = 37 PH, n = 40 non-PH)
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correlation with RVSP (ρ = 0.35; p = 0.074) both neared
statistical significance.
Interestingly, FVC/DLCO ratios (ρ = 0.53; p < 0.01)
were positively associated with bFGF, inversely associ-
ated with DLCO (ρ = −0.356; p = 0.046), and associatedwith high bFGF levels. HGF also was inversely associated
with DLCO (ρ = −0.33; p = 0.06).
Evaluating stability of biomarkers over time in controls
We then assessed the stability of serial biomarkers over
time in the control group. We found that all biomarkers,
Table 2 Biomarker levels in all patients with or without
pulmonary hypertension with scleroderma
Biomarkers PH (n = 37) No PH (n = 40) p value
IL-5 1.0 (0.7–1.6)
(n = 35)
1.4 (0.8–2.0)
(n = 35)
0.65
IL-8 7.2 (3.9–30.4) 5.7 (4.0–108.4)
(n = 39)
0.95
IL-12 2.0 (1.3–4.3)
(n = 35)
2.5 (1.5–4.5)
(n = 38)
0.44
TNF-α 9.2 (6.2–18.8) 6.5 (4.4–113.9) 0.53
VEGF 174.0 (101.6–317.3) 129.0 (75.6–446.7) 0.51
bFGF 11.0 (5.5–21.3)
(n = 33)
8.1 (4.0–19.3)
(n = 36)
0.52
PlGF 24.8 (16.3–31.0)
(n = 33)
19.7 (15.3–22.9)
(n = 33)
0.02
sFlt-1 101.8 (87.6–149.2) 89.7 (65.9–120.7) 0.02
HGF 241.1 (153.3–400.5) 181.6 (101.6–391.1) 0.17
Abbreviations: bFGF basic fibroblast growth factor, HGF hepatocyte growth
factor, IL interleukin, PH pulmonary hypertension, PlGF placental growth factor,
sFlt-1 soluble fms-like tyrosine kinase-1, TNF tumor necrosis factor, VEGF
vascular endothelial growth factor
Data are presented as median (interquartile range) in picograms per milliliter.
Numbers vary between cytokines and growth factors because of slight
variations in the number of values that were excluded from each group
(those values that were out of quantifiable range of the assay)
McMahan et al. Arthritis Research & Therapy  (2015) 17:201 Page 6 of 10except for VEGF (p = 0.03), were stable over time, with
no significant difference in levels between the early and
late time points (Additional file 2: Table S2).
Discussion
The major finding in our study was that clear associa-
tions exist between regulators of angiogenesis (sFlt-1
and PlGF) and measures of pulmonary vascular disease
and that these growth factors are potential biomarkers
for scleroderma-related PH. Both sFlt-1 and PlGF were
associated with PH and clinical markers of vascular dis-
ease. sFlt-1 levels were positively correlated with FVC/
DLCO ratio and RVSP and inversely correlated with
DLCO, and PlGF levels were also positively correlated
with FVC/DLCO and inversely correlated with DLCO.
These patterns were not evident for the other bio-
markers. In addition, both PlGF and sFlt-1 were signifi-
cantly associated with Raynaud’s severity scores. Levels
of both PlGF and sFlt-1 were stable over time in the
control population.
Interestingly, PlGF was recently studied as a predictor of
vascular complications related to Raynaud’s phenomenon
in scleroderma [3]. This study demonstrated that elevated
PlGF levels in scleroderma predict new digital ulcers,
highlighting a potential role of PlGF in scleroderma-
related vascular disease [3]. In a prior study done at our
center, investigators evaluated PlGF and other factors in
scleroderma as potentially relevant biomarkers for vascular
disease in scleroderma. In that cross-sectional study of 113
patients with scleroderma, PlGF levels were markedlyhigher in patients with scleroderma than in control
subjects (p < 0.0001) and were associated with echo-based
estimates of RVSP levels (p = 0.037). These data are con-
sistent with those in our current survey, supporting the
association of circulating PlGF and pulmonary vascular
disease.
sFlt-1 is a tyrosine kinase inhibitor that is released
from endothelial cells and monocytes. sFlt-1 acts through
the circulation to disrupt the interaction of PlGF and
VEGF with endothelial cell surface receptors [16]. The
endothelial cell response to VEGF is enhanced by high
circulating levels of PlGF in many disorders [4], and
VEGF and PlGF are required for endothelial cell homeo-
stasis [24]. Endothelial cell dysfunction is thought to play
a major role in the development of PH. In theory, PAH
may be a consequence of an endothelial cell influence
on vascular smooth muscle, either by releasing factors
that stimulate smooth muscle proliferation or by failing
to release relevant inhibitory factors [21]. Evidence also
suggests that endothelial injury and/or dysfunction also
plays a role in the development of PH associated with
interstitial lung disease (ILD) and PVH [12].
Although the classifications of PH within scleroderma
are currently divided between PAH, PH associated with
lung disease, and PH associated with left heart disease,
with currently available testing, we cannot exclude the
presence of PAH in patients with existing lung and left
heart disease in scleroderma, and there is no evidence
that the affected biological pathways within these sub-
groups in scleroderma are entirely distinct. For example,
when fitting patients with scleroderma into the current
PH classification system, we assume that the presence of
ILD excludes the presence of PAH, but this may not be
true, as the two may coexist in the context of a common
underlying disease process (scleroderma). Such clearly
demarcated distinctions between these subsets of pa-
tients may be somewhat artificial, as there is likely over-
lap between PH groups. The lack of a difference in levels
of sFlt-1 and PlGF among distinct PH subsets supports
the idea that there may be some common disease mech-
anisms across the scleroderma PH subsets. Further con-
firmatory studies to evaluate this question are needed.
There are several potential limitations to our study. It
remains unclear whether the elevated biomarkers levels
are specific for scleroderma pulmonary vascular disease
or if they are influenced by other scleroderma features,
such as peripheral vascular disease or active tissue injury
with fibrosis. We also did not control for the possible
influence of medications. Second, this was an un-
matched study, and comparison groups were slightly
different at baseline, with the PH group being slightly
older and having more significant RVD.
Because this was a pilot study meant to identify poten-
tially useful biomarkers in a small group of patients, we
Fig. 2 Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) levels associate with measures of cardiopulmonary severity in
scleroderma. a and b PlGF levels inversely correlate with diffusing capacity for carbon monoxide (DLCO) (ρ = −0.31; p = 0.01; n = 70)
and positively correlate with forced vital capacity (FVC)/DLCO ratio (ρ = 0.26; p = 0.03; n = 70). c–e sFlt-1 levels inversely correlate with
DLCO (ρ = −0.29; p = 0.01; n = 76) and positively correlate with right ventricular systolic pressure (RVSP) (ρ = 0.32; p = 0.01; n = 61) and
FVC/DLCO ratio (ρ = 0.23; p = 0.04; n = 76). Low DLCO, high RVSP, and high FVC/DLCO ratio are measures of pulmonary vascular disease
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Fig. 3 Placental growth factor (PlGF) levels are associated with severity of peripheral vascular manifestations in scleroderma. a PlGF levels correlate
with Raynaud’s phenomenon (RP) severity as measured with the Raynaud’s Medsger severity scale (ρ = 0.29, p = 0.02; n = 71). b Soluble fms-like
tyrosine kinase-1 (sFlt-1) levels correlate with Raynaud’s severity (ρ = 0.23, p = 0.04; n = 77)
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tensive multivariable analyses, as this is best addressed
in larger longitudinal studies. Despite our small popula-
tion, the same two biomarkers (sFlt-1 and PlGF) were
consistently associated with PH and its associated clin-
ical measures, suggesting that this was not simply due to
a type II error. Assessing biomarker levels at only two
points in time is a limitation, as some biomarker levels
can be highly variable. These levels will need to beassessed at multiple time points in a follow-up longitu-
dinal cohort study. We do recognize that a prediagnosis
sample may not be predisease; however, this evaluation
is still relevant in a population of undiagnosed pre-PH
patients, as they are evolving along a biological con-
tinuum, and these findings may provide some insight
into disease mechanisms. Finally, we did not include a
non-scleroderma control group, because our focus was
scleroderma-related pulmonary vascular disease.
Table 3 Association of biomarker levels at the early time point
with the later diagnosis of pulmonary hypertension
Biomarker PH (n = 12) No PH (n = 21) p value
IL-5 1.1 (1.0–1.7) 1.0 (0.8–1.7) 0.38
IL-8 17.5 (6.01–153.2) 7.6 (5.2–19.4) 0.20
IL-12 2.9 (2.0–8.2) 1.8 (1.5–3.3) 0.03
TNF-α 7.2 (4.6–22.3) 5.9 (4.3–10.0) 0.50
VEGF 386.7 (183.1–661.6) 388.81 (199.0–498.2) 0.91
bFGF 16.8 (7.1–42.7) 11.8 (6.3–19.5) 0.41
PlGF 24.9 (20.9–26.8) 19.3 (15.1–24.8) 0.07
sFlt-1 124.0 (101.5–138.5) 99.2 (84.2–113.0) 0.02
HGF 249.0 (148.1–568.0) 176.1 (139.2–253.9) 0.18
Abbreviations: bFGF basic fibroblast growth factor, HGF hepatocyte growth
factor, IL interleukin, PH pulmonary hypertension, PlGF placental growth
factor, sFlt-1 soluble fms-like tyrosine kinase-1, TNF tumor necrosis factor,
VEGF vascular endothelial growth factor
Data are presented as median (interquartile range) in picograms per milliliter
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Our survey provides compelling evidence that sFlt-1 and
PlGF levels are associated with measures of pulmonary
vascular disease and that these growth factors may be
potential biomarkers for scleroderma PH. The associ-
ation of these factors and PH also suggest that they may
play a biological role in the pathogenesis of PH. This survey
supports the need for larger, prospective, randomized stud-
ies to extend these preliminary observations.
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